Stephen H. Willard


S. Alan Stern Executive and Financial Management, Corporate and Government Oversight, Law
B.A., Williams College, 1982
J.D., Yale Law School, 1985


Steve Willard is the Chief Executive Officer of NRx Pharmaceuticals. He has been the chief executive officer of both private and public companies in the bio/pharmaceutical sector. He has practiced law in New York, London and Washington D.C. and was an investment banker for a time.

From 2012 to 2021, Willard served as chief executive officer of Cellphire Therapeutics. He built the company from 5 to 55 people, completed two successful clinical trials and initiated a third one, and increased the stock price 2000%. The company has a revolutionary method of storing human platelets for years, rather than the current 5-7 days.

From 2005 to 2012, Willard served as CEO and then Chairman of Flamel Technologies, S.A., a NASDAQ – traded international pharmaceutical controlled release technology company. He has developed, executed and managed multinational partnerships and corporate transactions worldwide.

Willard was a member of the Board of Directors of ETRADE Financial and/or its bank from 2000-2014, where he had stints as Chairman of the Bank Audit Committee, Head of Risk Oversight Committee, and Vice-Chairman. Willard is highly experienced with boards of directors on both the management, and outside board member, roles.

Willard has a unique background in financial institutions, having served as Associate Director of Resolutions for the Federal Deposit Insurance Corporation (FDIC), an SES-2 level position, from 1991-1994. He managed the resolution of the nation’s largest troubled banks during this period. His decisions were favorably reviewed in multiple Government Accountability Office (GAO) audits.

Willard is a member of the National Science Board’s class of 2018-2024.